The Journal of Urology
Volume 176, Issue 4 , Pages 1299-1306 , October 2006

Prevention of Benign Prostatic Hyperplasia Disease

  • Leonard S. Marks

      Affiliations

    • Urological Sciences Research Foundation and Department of Urology, Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California
    • Corresponding Author InformationCorrespondence: Urological Sciences Research Foundation, 3831 Hughes Ave., Suite 701, Culver City, California 90232 (telephone: 310-559-9800; FAX: 310-559-7821).
    • Financial interest and/or other relationship with Merck, Beckman-Coulter, Pfizer, Sanofi, Watson, Gen-Probe, GlaxoSmithKline and Diagnostic Ultrasound.
    • ,
  • Claus G. Roehrborn

      Affiliations

    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Gerald L. Andriole

      Affiliations

    • Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri

Received 19 September 2005

References 

  1. Marks LS . Treatment of men with minimally symptomatic benign prostatic hyperplasia—PRO (the argument in favor) . Urology . 2003;62:781
  2. Kaplan SA . Medical therapy for asymptomatic men with benign prostatic hyperplasia (primum non nocere) . Urology . 2003;62:784
  3. Di Silverio F , Gentile V , Pastore AL , Voria G , Mariotti G , Sciarra A . Benign prostatic hyperplasia (what about a campaign for prevention?) . Urol Int . 2004;72:179
  4. Rhodes T , Girman CJ , Jacobsen SJ , Roberts RO , Guess HA , Lieber MM . Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old . J Urol . 1999;161:1174
  5. Girman CJ , Panser LA , Chute CG , Oesterling JE , Barrett DM , Chen CC , et al.   Natural history of prostatism (urinary flow rates in a community-based study) . J Urol . 1993;150:887
  6. Homma Y , Imajo C , Takahahi S , Kawabe K , Aso Y . Urinary symptoms and urodynamics in a normal elderly population . Scand J Urol Nephrol Suppl . 1994;157:27
  7. Williams AM , Simon I , Landis PK , Moser C , Christens-Barry W , Carter HB , et al.   Prostatic growth rate determined from MRI data (age-related longitudinal changes) . J Androl . 1999;20:474
  8. Wright EJ , Fang J , Metter EJ , Partin AW , Landis P , Chan DW , et al.   Prostate specific antigen predicts the long-term risk of prostate enlargement (results from the Baltimore Longitudinal Study of Aging) . J Urol . 2002;167:2484
  9. Barry MJ , Fowler FJ , Bin L , Pitts JC , Harris CJ , Mulley AG . The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists . J Urol . 1997;157:10
  10. Jacobsen SJ , Girman CJ , Lieber MM . Natural history of benign prostatic hyperplasia . Urology . 2001;58(suppl):5
  11. AUA Practice Guidelines Committee . AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations . J Urol . 2003;170:530
  12. Roehrborn CG , Bruskewitz R , Nickel GC , Glickman S , Cox C , Anderson R , et al.   Urinary retention in patients with BPH treated with finasteride or placebo over 4 years (characterisation of patients and ultimate outcome) . Eur Urol . 2000;37:528
  13. Lucas MG , Stephenson TP , Nargund V . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia . BJU Int . 2005;95:354
  14. Baum NH . How to work up hematuria of unknown origin? . Postgrad Med . 2005;118:4
  15. Miller MI , Puchner PJ . Effects of finasteride on hematuria associated with benign prostatic hyperplasia (long-term follow-up) . Urology . 1998;51:237
  16. Hochberg DA , Basillote JB , Armenakas NA , Vasovic L , Shevchuk M , Pareek G , et al.   Decreased suburethral prostatic microvessel density in finasteride treated prostates (a possible mechanism for reduced bleeding in benign prostatic hyperplasia) . J Urol . 2002;167:1731
  17. Garraway WM , Russell EB , Lee RJ , Collins GN , McKelvie GB , Hehir M , et al.   Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men . Br J Gen Pract . 1993;43:318
  18. Roberts RO , Rhodes T , Panser LA , Girman CJ , Chute CG , Oesterling JE , et al.   Natural history of prostatism (worry and embarrassment from urinary symptoms and health care-seeking behavior) . Urology . 1994;43:621
  19. Roehrborn CG , Boyle P , Gould AL , Waldstreicher J . Serum prostate-specific antigen as a predictor of prostatic volume in men with benign prostatic hyperplasia . Urology . 1999;53:581
  20. Roehrborn CG , Boyle P , Bergner D , Gray T , Gittelman M , Shown T , et al.   Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate (results of a four-year, randomized trial comparing finasteride versus placebo) . Urology . 1999;54:662
  21. Roehrborn CG , McConnell JD , Lieber MM , Kaplan S , Geller J , Malek GH , et al.   Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia . Urology . 1999;53:473
  22. Roehrborn CG , Malice MP , Cook TJ , Girman CJ . Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH (a comprehensive analysis of the pooled placebo groups of several large clinical trials) . Urology . 2001;58:210
  23. Bosch JL , Bohnen AM , Groeneveld FP . Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years (the Krimpen Study) . Eur Urol . 2004;46:753
  24. McConnell JD , Roehrborn CG , Bautista OM , Andriole GL , Dixon CM , Kusek JW , et al.   The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia . N Engl J Med . 2003;349:2387
  25. Jacobsen SJ , Jacobson DJ , Girman CJ , Roberts RO , Rhodes T , Guess HA , et al.   Natural history of prostatism (risk factors for acute urinary retention) . J Urol . 1997;158:481
  26. Carter HB , Landis P , Wright EJ , Parsons JK , Metter EJ . Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? . J Urol . 2005;173:2040
  27. Bartsch G , Rittmaster RS , Klocker H . Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia . Eur Urol . 2000;37:367
  28. Carson C , Rittmaster R . The role of dihydrotestosterone in benign prostatic hyperplasia . Urology . 2003;61:2
  29. Bruchovsky N , Sadar MD , Akakura K , Goldenberg SL , Matsuoka K , Rennie PS . Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate . J Steroid Biochem Mol Biol . 1996;59:397
  30. Thigpen AE , Silver RI , Guileyardo JM , Casey ML , McConnell JD , Russell DW . Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression . J Clin Invest . 1993;92:903
  31. Thomas LN , Douglas RC , Vessey JP , Gupta R , Fontaine D , Norman RW , et al.   5α-Reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium . J Urol . 2003;170:2019
  32. Grino BB , Griffen JE , Wilson JD . Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone . Endocrinology . 1990;126:1165
  33. Avodart package insert . Research Triangle Park: GlaxoSmithKline; 2005;
  34. Proscar package insert . Whitehouse Station, New Jersey: Merck and Co; 1998;
  35. McConnell JD , Bruskewitz R , Walsh P , Andriole G , Lieber M , Holtgrewe HL , et al.  Finasteride Long-Term Efficacy and Safety Study Group   The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia . N Engl J Med . 1998;338:557
  36. Roehrborn CG , Boyle P , Nickel JC , Hoefner K , Andriole G  ARIA3001, ARIA3002 and ARIA3003 Study Investigators . Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia . Urology . 2002;60:434
  37. Andriole GL , Humphrey P , Ray P , Gleave ME , Trachtenberg J , Thomas LN , et al.   Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer . J Urol . 2004;172:915
  38. Iczkowski KA , Qiu J , Qian J , Somerville MC , Rittmaster RS , Andriole GL , et al.   The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate . Urology . 2005;65:76
  39. Marks LS , Partin AW , Dorey FJ , Gormley GJ , Epstein JI , Garris JB , et al.   Long-term effects of finasteride on prostate tissue composition . Urology . 1999;53:574
  40. Kaplan SA , Garvin D , Gilhooly P , Koppel M , Labasky R , Milsten R , et al.   Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride . Urology . 2000;56:610
  41. Andriole GL , Kirby R . Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia . Eur Urol . 2003;44:82
  42. Thompson IM , Goodman PJ , Tangen CM , Lucia MS , Miller GJ , Ford LG , et al.   The influence of finasteride on the development of prostate cancer . N Engl J Med . 2003;349:215
  43. Bostwick DG , Qian J , Civantos F , Roehrborn CG , Montironi R . Does finasteride alter the pathology of the prostate and cancer grading? . Clin Prostate Cancer . 2004;2:228
  44. Thompson, I. M.: New insights and developments from the Prostate Cancer Prevention Trial: the promise of SELECT. Available at http://webcasts.prous.com/aua2005. Accessed July 19, 2005
  45. Andriole GL , Roehrborn CG , Schulman C , Slawin KM , Somerville M , Rittmaster RS . Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia . Urology . 2004;64:537

 Supported by an unrestricted educational grant from GlaxoSmithKline, Philadelphia, Pennsylvania.

PII: S0022-5347(06)01390-5

doi: 10.1016/j.juro.2006.06.022

The Journal of Urology
Volume 176, Issue 4 , Pages 1299-1306 , October 2006

Article Tools

* Image Usage & Resolution